Leukemia Posts on Medivizor
Navigation Menu

Leukemia Posts on Medivizor

Is dasatinib effective with chemotherapy in the treatment of Philadelphia-chromosome postitive ALL?

Posted by on Jun 9, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effect of dasatinib (Sprycel) in addition to intensive chemotherapy in the treatment of children and young adults with acute lymphoblastic leukemia (ALL). The study concluded that dasatinib with chemotherapy was a safe and effective way to treat ALL. Some background Acute lymphoblastic leukemia (ALL) is a...

Read More

Can tyrosine kinase inhibitors influence survival rates in chronic phase chronic myeloid leukemia?

Posted by on Jun 8, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the side effects of tyrosine kinase inhibitors and their impact on outcomes in chronic-phase chronic myeloid leukemia patients. This study concluded that severe side effects from tyrosine kinase inhibitors can cause decreased survival rates in these patients. Some background Tyrosine kinase inhibitors...

Read More

Does ibrutinib pre-treatment affect the outcomes of alloHCT for patients with CLL?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...

Read More

Is thiotepa-based reduced-intensity conditioning effective before cord blood stem cell transplantation?

Posted by on May 31, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effectiveness of thiotepa-based RIC in leukemia and lymphoma patients undergoing stem cell transplantation. The authors concluded that this treatment improved outcomes compared to standard RIC. Some background Before undergoing stem cell transplantation, patients with lymphoma or leukemia must undergo conditioning...

Read More

Can tyrosine kinase inhibitor treatment be stopped in CML patients with deep molecular response?

Posted by on May 29, 2018 in Leukemia | 0 comments

In a nutshell This study aimed to define the conditions necessary for stopping tyrosine kinase inhibitor treatment in patients with chronic myeloid leukemia. This study concluded that patients who maintain a deep molecular response have good molecular relapse-free survival and can be considered for treatment discontinuation. Some...

Read More

Lenalidomide and blood clots: low risk in CLL and NHL

Posted by on May 22, 2018 in Leukemia | 0 comments

In a nutshell This study examined the risk of venous thromboembolism (VTE, a blood clot that forms in the veins of the legs, arms, or groin) in patients treated with lenalidomide (Revlimid). The study concluded that the risk of VTE was low with lenalidomide treatment. Some background Lenalidomide is an effective treatment already used in multiple...

Read More